Silence is deafening when new drugs are not approved
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →’Tis the season for everything except helping small business owners
So far the 2016 election campaign has been about a lot of things — immigration, treatment of Gold Star families, tax returns, emails and email hacks. But one thing it has not been about is enabling the real people who make America great, our more than 3 million small business owners. You get the feeling Read More →
Read More →Teledyne’s second quarter revenues, profits, earnings per share down
Teledyne Technology revenues fell, profits fell and earnings per share fell during the second quarter, the company announced when it released second quarter earnings results Aug. 4. The Thousand Oaks-based industrial conglomerate saw second quarter revenues fall 6.7 percent from $573.6 million in 2015 to $534.9 million in 2016, which missed analyst estimates of $546.7 Read More →
Read More →Inphi completes sale of Rambus
Inphi completed the sale of its memory product business to Sunnyvale-based Rambus Aug. 4. The Santa Clara-based Inphi, which designs chips aimed at packing more memory onto Internet servers and increasing bandwidth, employs a large engineering force in Thousand Oaks. The sale will allow it to focus on its communications business. As part of the Read More →
Read More →CVS Health will not cover Amgen’s Neupogen in favor of Novartis biosimilar
CVS Health will no longer cover Thousand Oaks-based Amgen’s Neupogen on its standard drug plan in 2017, favoring the biosimilar Zarxio from Novartis. CVS, which is the second largest benefits manager behind Express Scripts and also owns the largest chain of drug stores in the U.S., said Aug. 2 it will choose biosimilar drugs over Read More →
Read More →Amgen buying rights to Advaxis cancer treatment
Thousand Oaks-based biotech giant Amgen said it will buy the rights to develop and commercialize a cancer immunotherapy treatment Aug. 2. Under the agreement, Amgen will pay Princeton, N.J.-based Advaxis $40 million and buy $25 million worth of Advaxis common stock for the rights to develop and commercialize a preclinical cancer immunotherapy, which is designed Read More →
Read More →Land O’Lakes completes Ceres acquisition
Minneapolis-based Land O’Lakes completed its acquisition of Thousand Oaks-based ag-biotech company Ceres on Aug. 1. On June 17, Land O’Lakes, an ag and food conglomerate that had $13 billion in sales in 2015, announced it would buy Ceres for $17.2 million. For about two decades, Ceres had been devoted to developing biofuels using crops like Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
